Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma: A possible marker for serosal invasion and metastasis

Cancer

Volumn 86, Issue 10, 1999, Pages 1929-1935

  Yoshikawa, Takaki ^a   Saitoh, Mitsunori ^a   Tsuburaya, Akira ^a   Kobayashi, Osamu ^a   Sairenji, Motonori ^a   Motohashi, Hisahiko ^a   Yanoma, Shunsuke ^a   Noguchi, Yoshikazu ^b  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Diagnosis; Gastric carcinoma; Invasion; Metastasis; Plasma; Tissue inhibitor of matrix metalloproteinase 1 (TIMP 1)

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA;

CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0033570931     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991115)86:10<1929::AID-CNCR8>3.0.CO;2-C     Document Type: Article

References (29)

1. Tsuchiya Y, Sato H, Endo Y, Okada Y, Mai M, Sasaki T, et al. Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res 1993;53:1397-402.
2. Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1995;14:234-45.
3. Urbanski SJ, Edwards DR, Hershfield N, Hucheroft SA, Shaffer E, Sutherland L, et al. Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn Mol Pathol 1993;2:81-9.
4. Denhardt TD, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinase (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 1993;59:329-41.
5. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
6. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 1996;69:9-16.
7. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, et al. Clinical significance of tissue inhibitor of metallo-proteinase expression in gastric carcinoma. Br J Cancer 1997;76;531-6.
8. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 1994;70:506-12.
9. Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 / tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 1997;74:220-3.
10. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 1st English edition. Tokyo: Kanehara, Inc., 1995.
11. Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tisssue inhibitor of metalloproteinases. J Immunol Methods 1990; 127:103-8.
12. Stell DA, Carter CR, Stewart I, Anderson JR. Prospective comparison of laparoscopy, ultrasonography and computed tomography in the staging of gastric cancer. Br J Surg 1996; 83(9):1260-2.
13. Segal AW, Healy MJ, Cox AG, Wiliams I, Slavin G, Smithers A, et al. Diagnosis of gastric cancer. BMJ 1975;2:669-72.
14. Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. Semin Oncol 1996;23(3):307-15.
15. Horie Y, Miura K, Matsui K, Yukimasa A, Ohi S, Hamamoto T, et al. Marked elevation of plasma carcinoembrionic antigen and stomach cancer. Cancer 1996;77:1991-7.
16. Koga T, Kano T, Souda K, Oka N, Inokuchi K. The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg 1987;17:342-7.
17. Wobbes T, Thomas CMG, Segers MFC, Nagengast FM. Evaluation of seven tumor markers (CA50, CA19-9, CA19-9 TruQuant, CA72-4, CA195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer 1992;69:2036-41.
18. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993;7:1434-41.
19. Takino T, Sato H, Yamamoto E, Seiki M. Molecular cloning of a gene potentially encoding a novel matrix metalloproteinase having a transmembrane domain at the carboxyterminus. Gene 1995;115:293-8.
20. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinases expressed on the surface of invasive tumor cells. Nature 1994;370:61-5.
21. Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, et al. Expression of genes encoding type IV colloagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992;7:77-83.
22. Kaibara N, Iitsuka Y, Kimura A, Konayashi Y, Hirooka Y, Nishidoi H, et al. Relationship between area of serosal invasion and prognosis in patients with gastric carcinoma. Cancer 1987;60:136-9.
23. Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, et al. Prophylaxis with carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992;339:629-31.
24. Ichiyoshi Y, Maeda Y, Tomisaki S, Oiwa H, Sakaguchi Y, Ohno S, et al. Macroscopic intraoperative diagnosis of serosal invasion and clinical outcome of gastric cancer. Risk of underestimation. J Surg Oncol 1995;59:255-60.
25. Ohgami M, Kumai K, Otani Y, Wakabayashi G, Kubota T, Kitajima M. Laparoscopic wedge resection of the stomach for early gastric cancer using a lesion-lifting method. Dig Surg 1994;11:64-7.
26. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H. Surgical management for gastric cancer: the Japanese approach. Semin Oncol 1996;23:360-8.
27. Halvorsen RA Jr., Yee J, McCormick VD. Diagnosis and staging of gastric cancer. Semin Oncol 1996;23:325-35.
28. Maehara Y, Moriguchi S, Kakeji Y, Kohnoe S, Korenaga D, Haraguchi M, et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 1991;110:820-3.
29. Koga S, Kishimoto H, Tanaka K, Kawaguchi H. Clinical and pathological evaluation of patients with recurrence of gastric cancer more than five years postoperatively. Am J Surg 1978;136:317-21.